Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 8/20 | 0.36 |
| ▸ | HTR1D | P28221 | 3/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15829267 | 0.87 | KMT2A (0.44) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL31027466 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL30542341 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL25372479 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL22339346 | 0.74 | CYP11B1 (0.47) | ALDH1A1KMT2AMEN1KIF11NPC1 | |
| SCHEMBL24364799 | 0.72 | CYP1A2 (0.33) | HTR1DADRA1AADRA2AADRA2BADRA2C | |
| SCHEMBL13244816 | 0.72 | CA2 (0.50) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL18608306 | 0.72 | KMT2A (0.61) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL22792663 | 0.72 | ALDH1A1 (0.36) | ALDH1A1HPGDALOX15HSD17B10KMT2A | |
| SCHEMBL10585635 | 0.71 | HDAC1 (0.35) | MAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11566025-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-01-31 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200223845-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-07-16 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10633378-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-04-28 | — | — | US | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20160297810-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-10-13 | — | — | US | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
| US-20120077805-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566025-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 4277/4885HPGD 3073/4885ALOX15 3293/4885 |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 4277/4885HPGD 3073/4885ALOX15 3293/4885 |
| US-20160297810-A1 | NOVEL VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, IRF3 | ALDH1A1 4494/4885HPGD 3644/4885ALOX15 3508/4885 |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | ALDH1A1 1812/4885HPGD 262/4885ALOX15 1156/4885 |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | PIGS, GPR174, GPR17 | ALDH1A1 1098/4885HPGD 481/4885ALOX15 2434/4885 |
| US-20120077805-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | GABRA5, GABRA3, GABRA6 | ALDH1A1 2225/4885HPGD 1215/4885ALOX15 2913/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 4277/4885HPGD 3073/4885ALOX15 3293/4885 |
| US-10633378-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 4277/4885HPGD 3073/4885ALOX15 3293/4885 |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | ALDH1A1 2185/4885HPGD 2280/4885ALOX15 3527/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | ALDH1A1 2009/4885HPGD 2208/4885ALOX15 3386/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885HPGD 1812/4885ALOX15 2070/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | ALDH1A1 2009/4885HPGD 2208/4885ALOX15 3386/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | ALDH1A1 4277/4885HPGD 3073/4885ALOX15 3293/4885 |
| US-20200223845-A1 | NOVEL VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, IRF3 | ALDH1A1 4494/4885HPGD 3644/4885ALOX15 3508/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | ALDH1A1 2009/4885HPGD 2208/4885ALOX15 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.